Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma

Project: Research project

Project Details

Description

Characterize EZH inhibitor resistant lymphoma cell lines and use RNA and DNA seq analysis to determine the molecular basis of resistance of these cell lines. EZH2 mutants will be created and screened for their ability to resist the action of the inhibitor.

Identify and treat patients on EZH2 inhibitor clinical trials and obtain clinical information, blood specimens and fresh, frozen and paraffin fixed specimens from lymphoma patients to be assayed for gene expression studies and histone changes and correlated with pharmacokinetic data.
StatusFinished
Effective start/end date8/6/147/31/19

Funding

  • Joan and Sanford I. Weill Medical College of Cornell University (14040470//1R01CA187109-01)
  • National Cancer Institute (14040470//1R01CA187109-01)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.